NCT05297552View on ClinicalTrials.gov

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

February 28, 2025

Conditions
Muscle Invasive Bladder Carcinoma
Interventions
DRUG

RC48-ADC

Drug: RC48-ADC 2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle

DRUG

JS001

Drug: JS001 3.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle

Trial Locations (3)

100078

RECRUITING

Beijing Cancer Hospital, Beijing

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY